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Abstract
Parrot bornavirus 4 is an etiological agent of proventricular dilatation disease, a fatal neuro-
logic and gastrointestinal disease of psittacines and other birds. We tested the ability of riba-
virin, an antiviral nucleoside analog with antiviral activity against a range of RNA and DNA
viruses, to inhibit parrot bornavirus 4 replication in duck embryonic fibroblast cells. Two ana-
lytical methods that evaluate different products of viral replication, indirect immunocyto-
chemistry for viral specific nucleoprotein and qRT-PCR for viral specific phosphoprotein
gene mRNA, were used. Ribavirin at concentrations between 2.5 and 25 μg/mL inhibited
parrot bornavirus 4 replication, decreasing viral mRNA and viral protein load, in infected
duck embryonic fibroblast cells. The addition of guanosine diminished the antiviral activity
of ribavirin suggesting that one possible mechanism of action against parrot bornavirus 4
may likely be through inosine monophosphate dehydrogenase inhibition. This study dem-
onstrates parrot bornavirus 4 susceptibility to ribavirin in cell culture.
Introduction
Parrot bornavirus 4 (PaBV-4) is an enveloped, non-segmented, negative sense RNA virus in the
family Bornaviridae. Recent phylogenetic analysis of viruses within the family Bornaviridae,
which includes the formerly named Avian Bornavirus, resulted in new nomenclature and taxo-
nomic reorganization of Bornaviridae into 5 species:Mammalian 1 bornavirus, Psittaciform 1 bor-
navirus, Passeriform 1 bornavirus, Passeriform 2 bornavirus, andWaterbird 1 bornavirus [1].
Epidemiological and experimental results support that PaBV-1, -2, -3, -4, -7, all members of the
species Psittaciform 1 bornavirus, are etiological agents of proventricular dilatation disease (PDD),
a fatal neurologic and gastrointestinal syndrome of psittacines and other birds [2–4]. In infected
birds, the virus has a tropism for the brain and nervous tissue of psittacines [5–10], but can be
found in a majority of tissues including kidney, medullary cords of the adrenal gland, heart, spleen,
liver, lungs, pancreas, testes and ovary [7–10]. Bornaviruses are noncytopathic in cell culture [4,9].
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Presently, there is no proven efficacious treatment in birds against PaBV infections or for
reducing viral shedding. INF-α inhibits virus infection and viral load of the virus in quail cell
culture [11]. Non-steroidal anti-inflammatory drugs, to inhibit or reduce the inflammatory
reaction, are currently the principal treatment for PDD [12]. Celecoxid, meloxicam, and cyclo-
sporine are used clinically and experimentally with mixed results [12,13]. These drugs are
mainly symptomatic treatments of clinical PDD and their use may be contraindicated. In cock-
atiels experimentally infected with PaBV-4 and treated with meloxicam, severe weight loss and
depression was noted and upon necropsy and testing, there was pathological evidence of PDD
and increased PaBV-4 dissemination [14].
Ribavirin (1-ß-D-ribofuranosyl- 1,2,4-Triazole-3-carboxamide), a broad-spectrum antiviral
nucleoside analog [15], has in vitro and in vivo antiviral activity against a broad range of RNA
and DNA viruses. In human clinical practice, ribavirin is used, alone or in combination with
other drugs, in the treatment of infections with hepatitis C virus, respiratory syncytial virus,
and Lassa fever virus [16–21]. Experimentally in veterinary species, ribavirin shows antiviral
activity against foot-and-mouth disease virus [22], infectious salmon anemia virus [23], viral
hemorrhagic septicemia virus [24], and canine parainfluenza virus [25]. In mice, combination
treatment with ribavirin and baicalein provides better protection against influenza virus as
compared to the individual chemicals alone [26]. With specific regard to the family Bornaviri-
dae, ribavirin, at concentrations ranging from 1 to 10 μg/mL, inhibits the transcription of
Borna disease virus 1 (BoDV-1; speciesMammalian 1 bornavirus) in persistently infected
MDCK cells [27]. In neural cell lines infected with BoDV-1, viral titers and viral transcripts
decline when infected cells are treated with 20 μM ribavirin (4.9 μg/mL) [28].
Since BoDV-1 is prototypical of the family Bornaviridae, to which PaBV-4 is a member, the
current research was undertaken to evaluate in vitro antiviral effects of ribavirin and the combi-
nation of ribavirin with baicalein on PaBV-4 in infected duck embryonic fibroblast (DEF) cells
and to evaluate a potential mechanism of action. Our results demonstrated that ribavirin
decreased viral protein and mRNA expression in PaBV-4 infected cell cultures. The mecha-
nism of action was likely to include inhibition of inosine monophosphate dehydrogenase
(IMPDH) resulting in the reduction of intracellular guanosine nucleotide pools (GMP, GDP,
and GTP), and that minimal synergism with the addition of baicalein was demonstrated.
Materials and Methods
Media and cells
Duck embryonic fibroblast cells were obtained from stock cells previously grown for the study
by Gray et al [4]. To ascertain that the cells were not contaminated with any virus of the species
Psittaciform 1 bornavirus, an aliquot of the stored DEF cells was assayed by RT-PCR [29].
Throughout this study, DEF were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Life
Technologies Co., Grand Island, NY, USA) supplemented with 1% penicillin-streptomycin,
(10,000 U/mL—10,000 μg/mL) (Life Technologies Co.) and 5 or 10% bovine calf serum
(DMEM5% or DMEM10%, respectively) at 37°C in an atmosphere of 5% CO2.
For experiments, DEF cells were seeded into 24-well cell culture plates (BD, Franklin Lakes,
NJ, USA) and grown for 24 to 48 hours until cell layers were 70 to 80% confluent before infec-
tion with virus.
Antiviral compounds
Powdered ribavirin, 98% pure, was obtained from Sigma-Aldrich (St Louis, MO, USA) and
ribavirin capsules, 200 mg, were obtained from Sandoz Inc. (Princeton, NJ, USA). Ribavirin
solutions were made by dissolving ribavirin in DMEM with 2% bovine calf serum (DMEM2%).
Ribavirin and ABV
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Powdered, 98% pure, ribavirin was used in the cytotoxicity assay and in ribavirin inhibition
study 3; the contents of the ribavirin capsules were used in the cytotoxicity assay and in the
other studies except ribavirin inhibition study 3. Baicalein (Sigma-Aldrich) was dissolved in
PBS (Sigma-Aldrich) and DMEM5%.
Avian bornavirus
Parrot bornavirus 4 was obtained from a stock supply of virus that had been cultured and iso-
lated from experimentally infected Patagonia conures (Cyanoliseus patagonis) with clinical
PDD [4]. The virus was passaged in primary DEF cells maintained in DMEM5%. After 5 days
of incubation, virus infected DEF cells were harvested, freeze/thawed three times, and the
media-virus suspension was divided into 0.5 mL virus stock aliquots and stored at -80°C.
The virus stock was confirmed to be PaBV-4 by RNA extraction and RT-PCR analysis fol-
lowed by sequence analysis of the PCR product, as described previously [4,29,30]. Serial
10-fold dilutions of three stock virus aliquots assayed by indirect immunocytochemistry esti-
mated the mean (±SD) infectious titers at 12775 (±2467) ffu/mL.
Cytotoxicity assay
Cytotoxic effect to DEF cells of ribavirin, baicalein, and guanosine (Sigma-Aldrich) was deter-
mined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Vybrant MTT Cell Proliferation Assay Kit, Invitrogen, Eugene OR). DEF cells were grown in
96-well microplates (BD Falcon, BD) for 24 hours. Thereafter, the medium was replaced with
0.15 mL of DMEM10% containing either ribavirin ( 98% pure; concentrations ranging from
0.8 to 2000 μg/mL), the contents of the ribavirin capsules (0.8 to 2000 μg /mL), baicalein (0.01
to 50 μg /mL) or guanosine (1.5 to 140 μg /mL). DMEM10% without supplements, PBS, and
0.85 M Triton X (Sigma-Aldrich) in PBS served as controls. The cells were incubated for a fur-
ther 4 days before MTT assay was performed according to manufacturer’s recommendation. In
brief, the media was removed and 100 μL of fresh DMEM10% was added to each well. From a
stock solution of MTT (5 mg/mL), 10 μL was added to each well and incubated at 37°C in an
atmosphere of 5% CO2 for 4 hours. From a stock solution of sodium dodecyl sulfate (1 g in 10
mL 0.01 M HCl), 100 μL was added to each well, followed by an additional 10 hours incubation
at 37°C in an atmosphere of 5% CO2. Optical density at 570 nm was measured on each well
using a microplate spectrophotometer (Fluostar Omega, BMG Labtech, Ortenberg Germany)
and computer software program (Omega 1.30, BMG Labtech).
For each of the drugs, two independent experiments, each with 8 replicates per concentra-
tion, were performed. Results are report as a percent viability of untreated controls: DEF cells
incubated in DMEM10%.
Ribavirin inhibition studies
In study 1, the potential of ribavirin to inhibit PaBV-4 in infected DEF cells was examined.
DEF cells grown in 24-well plates were infected with 0.5 mL of either no PaBV-4 (negative con-
trol) or with virus at 128, 13, 1.3, 0.1, and 0.01 ffu/mL. The infected cells were incubated a fur-
ther 24 hours. Then, ribavirin solution, from ribavirin 200 mg capsules, was added, resulting in
final ribavirin concentrations of 0, 0.25, 2.5, or 25 μg/mL. The cells were incubated for a further
5 days, and then assayed by indirect immunocytochemistry. Three independent test runs with
2 replicates for each virus/ribavirin combination were tested.
In study 2, DEF cells were infected with 0.5 mL of control (no virus) or 128 and 13 ffu/mL
PaBV-4 stock. Following incubation for 24 hours, ribavirin solutions, made from ribavirin 200
mg capsules, were added resulting in final concentrations of 0, 2.5, 10, and 25 μg/mL ribavirin.
Ribavirin and ABV
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After 5 days, the medium was replaced with DMEM10% without ribavirin. Cells were incu-
bated a further 5 days in the absence of ribavirin before analysis by indirect immunocytochem-
istry. Four independent test runs with 2 replicates per each virus/ribavirin combination were
tested. Effective concentration 50% (EC50) and 90% (EC90) were estimated for cells infected
with 64 ffu PaBV-4 per well by fitting the data to a four-parameter logistic model to generate a
dose-response curve using SigmaPlot version 10.0.1 (Systat Software, Inc., San Jose, CA, USA).
In study 3, DEF cells grown in 24-well plates were infected with 0.5 mL of 13 or 128 ffu/mL
virus stock and incubated for 24 hours. Ribavirin solutions made from 98% pure ribavirin
were added to achieve final concentrations of 0, 2.5, 10.0, or 25.0 μg/mL ribavirin. After 5 days
of incubation, the media was removed and replaced with 1.0 mL of DMEM5% without ribavi-
rin. Cells were incubated for a further 0, 10, 14, and 21 days and then harvested for analysis by
qRT-PCR. Each virus/ribavirin/time combination was repeated on 3 independent experiments
and performed in duplicate.
In study 4, DEF cells grown in 24-well plates were infected with 0.5 mL of 128 or 13 ffu/mL
PaBV-4 stock. Following incubation for 24 hours, ribavirin solutions made from ribavirin 200
mg capsules were added, resulting in a final concentration of 0 or 25 μg/mL ribavirin. After one
or two days of incubation, the medium in a series of ribavirin treated wells was replaced with
1.0 mL of DMEM10% without ribavirin. In a third series of wells the medium containing riba-
virin remained on the cells for five days. Six days after the initial infection with PaBV-4, the
plates were analyzed by an indirect immunocytochemistry assay. The experiment was repeated
in 2 independent trails with duplicates for each virus/ribavirin/time sample.
Ribavirin-Guanosine inhibition study
DEF cells grown in 24-well plates were infected with 0.5 mL of 128 ffu/mL PaBV-4 stock and
then incubated for 24 hours. Thereafter, combinations of ribavirin and guanosine were added
to give a final concentration of 0, 10 or 25 μg/mL and 0, 3, 14 or 28 μg/mL, respectively. The
cells were incubated for a further 5 days before being assayed. Four independent trials with
duplicates of each ribavirin-guanosine combination were assayed by qRT-PCR and three inde-
pendent trials with duplicates of each ribavirin-guanosine combination were assayed by indi-
rect immunocytochemistry.
Ribavirin-Baicalein synergism study
DEF cells grown in 24-well plates were infected with 0.5 mL of 128 or 13 ffu/mL PaBV-4 stock,
incubated for 24 hours, then treated with 0.05 μg/mL baicalein and 5.0 μg/mL ribavirin individ-
ually or in combination for 5 days, and then assayed by qRT-PCR. Two independent experi-
ments with duplicates were run.
qRT-PCR
After the removal of the media from the DEF cell cultures, 300 μL of PBS was added to each
sample well and stored frozen at -80°C until assayed. Total viral RNA was isolated from 100 μL
of the PaBV-4 infected cell / PBS solution using the QIAamp viral RNA mini kit (Qiagen,
Valencia, Ca). Purified RNA was eluted in 60 μL elution buffer and stored at -80°C until use.
PaBV-4 phosphoprotein (P) gene mRNA was quantified using Taqman RRT-PCR assay
performed with TaqMan Fast Virus 1-Step Master Mix (Invitrogen,Carlsbad, Ca) and PaBV
phosphoprotein primers: 5’- AAGAAGAA[Y]CC[Y]TCCATG ATCTC-3’ and 5’-AA[Y]
TGCCGAAT[B]A[R]GTCATC- 3’, and Taqman probe 5’-FAM-TCGATAACTG [Y]
TCCCTTCCGGTC-BHQ-3’. Each reaction was carried out using 6 μl of total RNA, 0.25 μM
primers and 0.25 μM probe in a 12 μl final reaction volume. All reactions were carried out
Ribavirin and ABV
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using an ABI 7900HT, and cycling parameters were as follows: 5 min reverse transcription
(RT) step at 50°C, RT inactivation and polymerase activation for 1 min at 95°C, and 45 amplifi-
cation cycles at 95°C for 3 sec and 58°C for 30 sec. All samples were run in duplicate and Taq-
man RRT-PCR assay was repeated twice. Samples were considered negative when 37 CT.
In separate reactions cellular 18S rRNA was quantified using TaqMan Fast Virus 1-Step
Master Mix and Eukaryotic 18S rRNA FAM Endogenous Control (Invitrogen,Carlsbad, Ca)
according to the manufactures instructions. Reactions were carried out as described above in
an ABI 7900HT.
Analysis of qRT-PCR data was through the relative change in P gene mRNA expression,
which was calculated using the 2 - ΔΔCt method [31,32], where ΔΔCT = (CT P gene (treated)–CT
18s rRNA (treated))—(CT P gene (untreated)–CT 18s rRNA (untreated)).
Indirect immunocytochemistry assay
Indirect immunocytochemistry assay, to detect PaBV-4 nucleoprotein (N protein), was con-
ducted similar to a previously described method [4]. Briefly, the DEF cells were washed twice
for 5 min each time in 0.02 M PBS, fixed for 10 min in 2% paraformaldehyde in 0.02 M PBS,
and then washed twice for 5 min each time in 0.02 M PBS. Cells were permeabilized using 1%
Triton X-100/0.02 M PBS for 10 min and then washed 3 times for 5 min each time in 0.03%
Tween/0.02 M PBS. Blocking was performed for 2 hours in 5% dried milk/0.03% Tween/0.02
M PBS. The primary antibody, chicken IgG anti-PaBV-4 N protein, at a 1:500 dilution in 1%
dried milk/0.03% Tween/0.02 M PBS, was added to the cells and then incubated in a humidi-
fied chamber for 30 min at 37°C.
Cells were washed 3 times for 5 min each time in 0.03% Tween/0.02 M PBS. Secondary anti-
body, horseradish peroxidase conjugated rabbit anti-chicken IgG (Sigma-Aldrich) at a 1:500
dilution in 1% dried milk/0.03% Tween/0.02M PBS, was added to the cells and incubated in a
humidified chamber for 30 min at 37°C. Cells were washed 3 times for 5 min each time in
0.03% Tween/0.02M PBS and then rinsed in distilled water.
Digital image analysis to determine numbers of PaBV-4 positive cell foci
and area of infected cells
Digital images of 24 well plates stained by an indirect immunocytochemistry assay were made
using computerized software (VueScan 9, Hamrick Software, http://www.hamrick.com/) and
saved as uncompressed 8-bit grey-scale TIFF files.
The 8-bit grey-scale images were imported into an image analysis software program (Ima-
geJ, National Institutes of Health; http://rsb.info.nih.gov/ij/) [33]. Contrast of each plate image
was maximized using the auto brightness/contrast tool. Then using the threshold tool, black
and white contrast enhancement of each image was done using the brightness control bar, with
visual comparison being made to the original grey-scale images to ensure optimum visualiza-
tion of positively stained cell foci. The image was then converted to a binary image, with
infected cells being black, and saved as a TIFF file.
An equally sized area of interest, maximized to include as much of the well as possible, was
delineated in each well. The number of PaBv-4 positive cell foci per area of interest was counted
using the ImageJ Analyze Particles tool, with particle size gated between 0.0001 to infinity
square inch. The area of infected cells, measured as the percent area of black pixels per area of
interest, was determined using the macro function Calculate_Black_to_White_Ratio. A repre-
sentation of the wells and images is provided in Fig 1.
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Statistical analysis
Descriptive statistics of mean ± SD, with standard deviation calculated after 2-ΔΔCt transforma-
tion [32], were used to describe relative expression of mRNA. Statistical analysis of qRT-PCR
data was performed on mean ΔCt for the independent experimental repeats using One Way
Analysis of Variance (ANVOA) with Holm-Sidak method for pairwise comparisons (study 3
and Ribavirin-Guanosine inhibition study) [32]. Descriptive statistics of median, 25th and 75th
percentile were used to describe indirect immunocytochemistry results. Statistical analysis was
performed using ANOVA test on ranks with Tukey test for pairwise comparisons (study 2). A
P 0.05 was considered statistically significant. SigmaPlot version 10.0.1 was used for per-
forming all statistical analyses (Systat Software, Inc., San Jose, CA).
Results
Cytotoxicity of Ribavirin, Baicalein, and Guanosine
In order to examine for potential confounding factors of the antiviral agents and other com-
pounds on DEF cell viability, an MTT assay was used to examine the cytotoxicity of the com-
pounds on DEF cells. Cytotoxicity was not determined to be a confounding factor at the
concentrations of ribavirin, baicalein, or guanosine used for the virus inhibition experiments in
this study. When incubated with98% pure ribavirin (Fig 2A) or contents of ribavirin 200 mg
capsule (Fig 2B), cell viability for DEF cells was similar to control values across ribavirin con-
centrations used in the virus inhibition experiments. When DEF cells were incubated with
Fig 1. Digital image analysis to determine stained PaBV-4 positive cell foci and area of infected cells.
(A) Photograph after indirect immunocytochemistry of wells containing infected duck embryonic fibroblasts
infected with PaBV-4 and incubated with or without ribavirin. PaBV-4 nucleoprotein detected as dense
shades of grey. (B) Digital 8-bit grey-scale images of the same wells after digital scanning. (C) The same
wells after 8-bit grey scale images were enhanced and converted to a binary image for analyses using
ImageJ Analyze. The areas of N protein immunocomplex are in black. The area of interest that was analyzed
is the same for each well and is within the superimposed yellow circles.
doi:10.1371/journal.pone.0134080.g001
Ribavirin and ABV
PLOSONE | DOI:10.1371/journal.pone.0134080 July 29, 2015 6 / 17
Fig 2. Cytotoxicity on duck embryonic fibroblasts. (A) Cytotoxicity following incubation with HPLC grade ribavirin (> 98% pure). (B) Cytotoxicity following
incubation with ribavirin capsule contents. (C) Cytotoxicity following incubation with baicalein or guanosine. Data is depicted as median ± 25th and 75th
percentiles.
doi:10.1371/journal.pone.0134080.g002
Ribavirin and ABV
PLOSONE | DOI:10.1371/journal.pone.0134080 July 29, 2015 7 / 17
baicalein or guanosine (Fig 2C), cell viability remained constant across the range of concentra-
tions used in the virus inhibition experiments.
Ribavirin inhibition of PaBV-4
Study 1. This study was performed to determine appropriate doses for PaBV-4 infection
and ribavirin treatment. Sufficient numbers of PaBV-4-infected cells were detected only if DEF
cells were infected with at least 7 ffu (Table 1). PaBV-4 positive cell foci numbers and area of
infected cells decreased with the addition of 2.5 and 25.0 μg/mL ribavirin (Table 1).
Study 2. To determine the antiviral activity of differing concentrations of ribavirin, PaBV-
4 infected DEF cells were incubated with increasing concentrations of ribavirin for 5 days, fol-
lowed by 5 days incubation with DMEM10% without ribavirin. In cells infected with 64 ffu
PaBV-4, PaBV-4 positive cell foci were significantly (P<0.05) reduced when treated with 10
and 25 μg/mL ribavirin as compared to untreated control, 0, 8, and 56 positive cell foci, respec-
tively. PaBV-4 positive cell foci decreased in a dose dependent manner in cells infected with 7
ffu, 18, 1, 2 positive cell foci when treated with 0, 10, and 25 μg/mL ribavirin (Fig 3A). A similar
dose-dependent reduction in percent area of infected cells was observed (Fig 3B).
For the DEF cells infected with 64 ffu PaBV-4, the estimated EC50 and EC90, using positive
staining foci numbers, were 4.7 and 15.6 μg/mL ribavirin, respectively, and using area of
infected cells, were 0.5 and 19.7 μg/mL ribavirin, respectively.
Study 3. We investigated the expression of P gene mRNA and duration of time needed for
expression to rebound to levels of untreated cells following the removal of ribavirin. After 5
days of treatment with 2.5 to 25 μg/mL ribavirin, expression of P gene mRNA was significantly
(P 0.05) less than control of with no ribavirin treatment, ranging from a 4 to 6 fold difference
in expression (Fig 4). With the removal of ribavirin from the cells, P gene mRNA expression
rose in a time-dependent manner over 21 days, but remained significantly (P 0.05) reduced
for up to 14 days after removal of ribavirin.
Table 1. Reduction in viral load of infected duck embryonic fibroblast (DEF) cells following treatment with Ribavirin.
PaBV-4 positive cell foci Area of infected cells (%)
Virus (ffu) Ribavirin (μg/mL) Median (25th– 75th percentile) Median (25th– 75th percentile)
64 0 36 35–37 47.7 47.2–48.2
0.25 40 33–46 49.5 46.7–52.3
2.5 73 72–73 30.6 29.0–32.2
25.0 1 0.5–1.5 0.4 0.4–0.5
7 0 50 48–51 9.1 8.5–9.8
0.25 73 72–73 12.5 12.0–13.0
2.5 19 18–20 4.3 4.1–4.5
25.0 2 2–2 0.5 0.4–0.5
1 0 7 6–7 1.6 1.5–1.6
0.25 7 6–9 1.3 1.0–1.6
2.5 4 3–4 0.9 0.9–0.9
25.0 1 0–1 0.6 0.6–0.6
No virus (negative control) 0 0 0 0.2 0.2–0.3
0.25 1 0.5–1.5 0.2 0.2–0.2
2.5 0 0 0.4 0.4–0.4
25.0 1 0.5–1.5 0.7 0.6–0.8
Cells infected with 0.05 and 0.005 ffu had PaBV-4 positive cell foci and percent area of infected cells similar to No virus (negative control).
doi:10.1371/journal.pone.0134080.t001
Ribavirin and ABV
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Study 4. We investigated treatment duration time needed to decrease the viral load of
PaBV-4 infected cells. After only 24 hours of exposure to 25 μg/mL ribavirin, followed by 4
days of incubation without ribavirin, PaBV-4 positive foci numbers and percent area of
infected cells were less than in the untreated controls with virus (Fig 5).
Guanosine attenuation of anti-ABV activity of Ribavirin
To test whether depletion of GTP pools was a mechanism of action contributing to the antiviral
activity of ribavirin, 3 to 28 μg/mL guanosine was added to infected cells treated with ribavirin.
The addition of guanosine reduced the antiviral activity of ribavirin in a dose-dependent man-
ner. The relative expression of the P gene mRNA was significantly (P 0.05) increased,
between 3 to 5 fold increase, with the addition of 14 and 28 μg/mL of guanosine when com-
pared to when ribavirin was present without guanosine (Fig 6A).
Indirect immunocytochemistry analysis of infected cells for N protein yielded similar results
with numbers of PaBV-4 positive cell foci and area of infected cells increasing with 14 and
28 μg/mL guanosine (Fig 6B & 6C).
Baicalein
The effect of baicalein on the antiviral activity of ribavirin was investigated by comparing the
expression of P gene mRNA with and without treatments. With the addition of 5.0 μg/ml riba-
virin or with the combination treatment of ribavirin and baicalein, there was a 3.5 to 4.5 fold
reduction in mRNA expression as compared with no treatment control, however combination
treatment did not show mRNA decreasing more than ribavirin alone (Fig 7).
Fig 3. Anti-viral activity of Ribavirin on PaBV-4 in duck embryonic fibroblasts (DEF). (A) PaBV-4 positive cell foci, assessed by indirect
immunocytochemistry assay. (B) Percent area of infected cells, assessed by indirect immunocytochemistry assay. DEF infected with 64 ffu (black circle), 7
ffu of PaBV-4 (grey square), or no virus (white triangle), incubated with ribavirin for 5 days, and then incubated a further 5 days in the absence of ribavirin.
Data presents as median ± 25th and 75th percentile. *, compared with no added ribavirin (P <0.05, ANOVA on ranks with Tukey test).
doi:10.1371/journal.pone.0134080.g003
Ribavirin and ABV
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Discussion
In this study we demonstrated that ribavirin, at concentrations between 2.5 and 25 μg/mL, had a
dose-dependent inhibition on PaBV-4 replication as demonstrated by decreasing viral mRNA
and viral protein loads in infected DEF cells. This decrease was demonstrated using two analyti-
cal methods that evaluated different products of viral replication, indirect immunocytochemistry
assay for viral N protein and qRT-PCR for viral P gene mRNA expression. Viral protein synthe-
sis rapidly declined with ribavirin treatment; after 24 hours of incubation with 25 μg/mL ribavi-
rin, numbers of PaBV-4 infected cell foci and area of infected cells dropped to 2 and 9%,
respectively, of the levels in untreated infected cells. This most probably represents background
level of these assays, because similar values for infected cell foci and area of infected cells were
also obtained from non-infected control cells (Fig 5A and 5B). Additionally, following 5 day
exposure to 2.5 to 25 μg/mL ribavirin, there was between a 3 and 6 fold reduction in viral mRNA
expression (Figs 4 and 6A) and viral mRNA levels did not recover to control levels till up to14
days after ribavirin removal (Fig 4). Our findings are comparable to studies on BoDV-1, a closely
related bornavirus, where ribavirin inhibited transcription and reduced viral load in vitro
[27,28]. Our study used only PaBV-4 in DEF cells, but it would be interesting to examine the sus-
ceptibility of other members of the species Psittaciform 1 bornavirus in additional cells lines, as
most members of the family Bornaviridae exhibit cell specific tropism and growth characteristics
Fig 4. Post-exposure effect of Ribavirin on PaBV-4 P genemRNA expression. Duck embryonic
fibroblasts infected with 7 or 64 ffu PaBV-4, incubated with 0.0 (black diamond), 2.5 (open circle), 10.0 (open
square), or 25.0 (open triangle) μg/mL ribavirin. Cells analyzed by qRT-PCRwith results (mean ±SD) shown
as the fold change in P gene mRNA expression relative to the within day expression. *, compared with no
added ribavirin within day (P <0.05, ANOVA with Holm-Sidak method).
doi:10.1371/journal.pone.0134080.g004
Ribavirin and ABV
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[10] and different patterns of replication in various cell lines [34] and the efficacy of ribavirin
treatment shows virus genotype and cell line variability [35–37].
The study was were carried out with DEF cells; PABV-4 replicates well in DEF cells and is not
cytopathic [4,9]. The cytotoxic effect of ribavirin on DEF cells is unknown and varies with cell
lines [23,24,28,38–40]. An additional variable is that commercially available preparations have
compounding chemicals that may be toxic to cells in culture. Cytotoxic assays in our studied
showed that the pure ribavirin and the commercial ribavirin product affected cell viability at con-
centrations above 720 μg/mL, well below the studied concentrations of 2.5 to 25 μg/mL (Fig 2).
Better understanding of the mechanism by which ribavirin inhibits PaBV-4 replication is an
important step in its use in infected animals and will help elucidate the mechanisms of Bornavir-
idae infection and biology. There are a few excellent reviews on the proposed antiviral mecha-
nism of action for ribavirin [17–19,41–44]. Proposed mechanisms of action for ribavirin’s
antiviral activity include: (i) inhibition of inosine monophosphate dehydrogenase (IMPDH)
resulting in the depletion of intracellular guanosine nucleotides (GMP, GDP, and GTP) pools;
(ii) inhibition of viral RNA-dependent RNA-polymerase, RNA capping, and RNA synthesis;
(iii) lethal mutagenesis due to misincorporation of nucleotides; and, (iv) immunomodulatory
effects on Th1 and Th2 T lymphocytes. The mechanism by which ribavirin inhibits PaBV-4 rep-
lication is unknown. Our studies corroborate findings that one mechanism of action in ribavi-
rin’s antiviral activity on Bornaviridae is likely to be the inhibition of IMPDH causing
disruption in GTP required processes [28]. Though this is a proposed mechanism for ribavirin
in many viruses, it has been shown not to be a mechanism against Influenza A [45], Lassa virus
[46] and infectious salmon anemia virus [23]. Biologically, the implications of this mechanism
of action in the clinical patient is still questionable, for in the animal, intracellular guanosine
nucleotides pools are highly regulated and fine-tuned to provide for the cellular GTP needs [17].
Other mechanisms of action, such as mutated RNA, due to the misincorportation of cyti-
dine and uridine instead of guanine or adenine, may factor in to ribavirin’s antiviral activity
[23]. However, our study was not designed to investigate lethal mutagenesis or inhibition of
viral RNA-dependent RNA-polymerase, RNA capping, and RNA synthesis as mechanism of
Fig 5. Time dependency to reduce viral load. (A) PaBV-4 positive cell foci, assessed by indirect immunocytochemistry assay. (B) Percent area of infected
cells, assessed by indirect immunocytochemistry assay. DEF infected with 64 ffu (black circle), 7 ffu of PaBV-4 (grey square), or no virus (white triangle),
incubated for 0, 1, 2, or 5 days with 25μg/mL ribavirin. Data presents as median ± 25th and 75th percentile.
doi:10.1371/journal.pone.0134080.g005
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Fig 6. Guanosine inhibition of ribavirin antiviral activity on PaBV-4. (A) qRT-PCR results reported as
mean (±SD) relative change in P gene mRNA expression, compared to control group (neither guanosine nor
ribavirin added). *, compared with no guanosine within ribavirin treatment group (P <0.05, ANOVA with Holm-
Sidak method). (B) Indirect immunocytochemistry results presented as median ± 25th and 75th percentiles
positive stained cell foci. (C) Indirect immunocytochemistry results presented as median ± 25th and 75th
percentiles of the percentage area of infected cells.
doi:10.1371/journal.pone.0134080.g006
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actions. Additionally, it could not evaluate the immunomodulatory effects of ribavirin. Immu-
nomodulation and the amelioration of the inflammatory response in-vivomay be an important
aspect in ribavirin’s clinical application and efficacy [47]. An inflammatory reaction in infected
neurons is seen in clinical cases of PaBV [48], as well as being part of the pathology in BoDV-1
[49]. Further studies on the mechanisms of action of ribavirin would be useful.
In investigating potential synergism of baicalein and ribavirin, the combination of drugs at a
1:100 ratio of Baicalein/Ribavirin did not appreciably increase the antiviral activity of ribavirin,
there was less than a 1-fold reduction of P gene mRNA expression between ribavirin and ribavirin
with the addition of baicalein. This is not consistent with the dose-dependent reduction of influ-
enza A viral matrix protein gene expression seen by Chen et al [26]. These differing results may
be due to baicalein’ s mechanism of action and PaBV-4 replication/infection cycle as compared to
influenza. The mechanism of action for baicalein’ s antiviral activity is not well elucidated but is
reported to be through blocking virus binding and entry into the cell [50–52] and inhibition of
the enzymatic activity of reverse transcriptase [53]. Bornaviruses enter the cell through a
Fig 7. Potential anti-viral synergism of baicalein and ribavirin on PaBV-4. Duck embryonic fibroblasts
infected with 7 (white hashed bars) or 64 (grey bars) ffu PaBV-4, incubated with 0.05 μg/mL baicalein, 5.0 μg/
mL ribavirin, both drugs or neither. Cells were analyzed by qRT-PCR with results (mean ±SD) shown as the
fold change in P gene mRNA expression relative to the expression of the groups treated with neither drug.
doi:10.1371/journal.pone.0134080.g007
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receptor-mediated endocytosis and pH dependent fusion [54], and spreads mainly through a cell-
to-cell transfer between contiguous cells [55], possibly in the form of a ribonucleoprotein complex
[56]; this has yet to be fully elucidated for PABV. The specific mechanisms for the lack of individ-
ual or synergetic antiviral activity of baicalein on PaBV-4 were outside the scope of this project.
But a method procedural difference between the two studies should be noted; whereas Chen et al.
infected and treated cells simultaneously, we allowed a 24-hour incubation of DEF cells with
PaBV-4 prior to any antiviral treatment. Our procedure was to simulate that viral infection would
have occurred prior to ribavirin treatment in naturally infected animals.
Conclusion
To our knowledge, this is the first report showing that the ribavirin significantly inhibits PaBV-
4 replication in cell culture. We presume that the inhibitory effect on PaBV-4 replication may
be mediated by IMPDH inhibition, but other mechanism such as lethal mutagenesis and inhi-
bition on viral RNA-dependent RNA-polymerase, RNA capping, and RNA synthesis may be
factors. These findings, and ribavirin’s immunomodulation properties, suggest that further
studies on ribavirin’s pharmacokinetics, toxicity, and treatment efficacy against PaBV 1–7 in
naturally and experimentally infected birds should be investigated.
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